Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — November 2015

Planlagt Fastgjort Låst Flyttet Genmab
2.4k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • D Offline
    D Offline
    dohk
    wrote on sidst redigeret af
    #2417

    Link Preview Image
    FDA approves new Bristol-Myers treatment for multiple myeloma

    The U.S. Food and Drug Administration said on Monday it had approved a drug to be sold by Bristol-Myers Squibb Co as a treatment for a form of blood cancer. The FDA said it approved the treatment, Empliciti, to be used in multiple myeloma patients in combination with Celgene Corp's Revlimid and common anti-inflammatory drug dexamethasone. The National Cancer Institute estimates there will be 26,850 new cases of multiple myeloma and 11,240 related deaths in the United States in 2015.

    favicon

    Yahoo Finance (finance.yahoo.com)

    1 Reply Last reply
    0
    • D Offline
      D Offline
      dohk
      wrote on sidst redigeret af
      #2418

      Så kom emplicit godkendelsen.

      1 Reply Last reply
      0
      • J Offline
        J Offline
        Jedi
        wrote on sidst redigeret af
        #2419

        PFS 19.4 mdr med Elo-Len-Dex (14.9 mdr med Len-Dex alene) - det er den PFS Dara-Len-Dex gerne skal slå i Pollux studiet. Kan vi få en indikation af PFS fra Dara-Len-Dex fase 2 kombi studiet på ASH?

        1 Reply Last reply
        0
        • J Offline
          J Offline
          Jedi
          wrote on sidst redigeret af
          #2420

          Access to this page has been denied

          px-captcha

          favicon

          (seekingalpha.com)

          1 Reply Last reply
          0
          • M Offline
            M Offline
            Mcjean
            wrote on sidst redigeret af
            #2421

            http://oasm.finanstilsynet.dk/dk/vismeddelelse.aspx?aid=5fb5cd59-0024-471a-b561-b3eff2b89715 31 aug. 59.322.130 stk - nu 209.133 stk's flere aktier. Nogen der kan

            1 Reply Last reply
            0
            • M Offline
              M Offline
              Mcjean
              wrote on sidst redigeret af
              #2422

              se udnyttelsesgraden og sige et eller andet begavet om det?

              1 Reply Last reply
              0
              • BulderB Offline
                BulderB Offline
                Bulder
                wrote on sidst redigeret af
                #2423

                Hvorfor er der to dara/len(rev)
                /dex studier - Gen503 og Pollux?

                1 Reply Last reply
                0
                • SolsenS Offline
                  SolsenS Offline
                  Solsen
                  wrote on sidst redigeret af
                  #2424

                  Har nu mere ondt af Marshall Wace 😉

                  1 Reply Last reply
                  0
                  • SolsenS Offline
                    SolsenS Offline
                    Solsen
                    wrote on sidst redigeret af
                    #2425

                    Gen503 var jo et fase 1/2 dose escalation study, dar var baggrunden for Pollux.

                    1 Reply Last reply
                    0
                    • BulderB Offline
                      BulderB Offline
                      Bulder
                      wrote on sidst redigeret af
                      #2426

                      Jamen Gen503 er jo det
                      der kommer på ASH nu

                      1 Reply Last reply
                      0
                      • Legolas23L Offline
                        Legolas23L Offline
                        Legolas23
                        wrote on sidst redigeret af
                        #2427

                        Kommer der nyt fra både Castor og Pollux ?

                        1 Reply Last reply
                        0
                        • BudweisB Offline
                          BudweisB Offline
                          Budweis
                          wrote on sidst redigeret af
                          #2428

                          Fra dagens Deutche analyse af pharma og biotek sektoren i EU - "In our view Actelion, Genmab and SOBI are the most likely takeout targets as they have strong recently approved potential blockbuster products and better shareholder structure"

                          1 Reply Last reply
                          0
                          • SolsenS Offline
                            SolsenS Offline
                            Solsen
                            wrote on sidst redigeret af
                            #2429

                            🙂 Let it come

                            1 Reply Last reply
                            0
                            • Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktør
                              wrote on sidst redigeret af
                              #2430

                              Tak Budweis. 🙂

                              1 Reply Last reply
                              0
                              • SolsenS Offline
                                SolsenS Offline
                                Solsen
                                wrote on sidst redigeret af
                                #2431

                                Over 100 sider fra Deutsche !

                                1 Reply Last reply
                                0
                                • BudweisB Offline
                                  BudweisB Offline
                                  Budweis
                                  wrote on sidst redigeret af
                                  #2432

                                  nemlig - det er en solid rapport

                                  1 Reply Last reply
                                  0
                                  • Legolas23L Offline
                                    Legolas23L Offline
                                    Legolas23
                                    wrote on sidst redigeret af
                                    #2433

                                    Dissekerer de pipelinen op i kurspoint ? Det kunne være interessant at høre, hvor meget de enkelte produkter er normeret til ?

                                    1 Reply Last reply
                                    0
                                    • BudweisB Offline
                                      BudweisB Offline
                                      Budweis
                                      wrote on sidst redigeret af
                                      #2434

                                      nope

                                      1 Reply Last reply
                                      0
                                      • BudweisB Offline
                                        BudweisB Offline
                                        Budweis
                                        wrote on sidst redigeret af
                                        #2435

                                        genmab analysen er på tre sider

                                        1 Reply Last reply
                                        0
                                        • digafarmD Offline
                                          digafarmD Offline
                                          digafarm
                                          wrote on sidst redigeret af
                                          #2436

                                          Er det noget man kan tilgå Budweis? 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger